In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

A large clinical trial has shown that oral semaglutide significantly reduces cardiovascular events in people with type 2 ...

A recent study highlights the effectiveness of Semaglutide, an anti-diabetes drug, in reducing the risk of heart attacks and ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...